# US 2025/0145682 A1 · Compositions and methods of treating tissue damage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145682 A1
- Document ID: US20250145682A1
- Status: Published application
- Kind: A1
- Application number: 18/887,949
- Filed: 2024-09-17
- Published: 2025-05-08
- Earliest claimed: 2015-10-02
- Assignees: Silver Creek Pharmaceuticals, Inc.
- Applicants: Silver Creek Pharmaceuticals, Inc.
- Inventors: Laura D.J. Antipov; Shawdee Eshghi; Kristopher M. Kuchenbecker; Bjorn L. Millard; Matthew D. Onsum; Andrea D. Nickerson; Timothy R. Stowe; Yan Zhang
- Web page: https://patentgrep.com/patent/US20250145682A1

## CPC

- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- C07K 14/765: Serum albumin, e.g. HSA
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.

## Claims

### Claim 1

A method to treat tissue damage, the method comprising:
administering topically to the patient in need thereof a topical composition comprising (a) a therapeutically effective amount of the bi-specific protein having (i) an activator domain, wherein the activator domain comprises a variant of human insulin-like growth factor IGF-1 having at least 95% identity to wild type human IGF-1 and comprising one or more mutations, wherein the one or more mutations consist of a substitution at one or more positions corresponding to E3, Y24, Y31, Y60, and combinations thereof, and (ii) a targeting domain, wherein the targeting domain comprises a variant of human Annexin A5 having at least 95% identity to wild type human Annexin A5 and comprising one or more mutations, wherein the one or more mutations consist of a substitution at the position corresponding to C316 and optionally at one or more positions corresponding to R63, K70, K101, E138, D139, N160 and combinations thereof, and (b) a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein the topical composition is a solution, a suspension, or an emulsion.

### Claim 3 (depends on 1)

The method of claim 1, wherein the topical composition is a suspension and wherein the topical composition further comprises an emulsifying agent.

### Claim 4 (depends on 1)

The method of claim 1, wherein the Annexin A5 variant targets the bi-specific protein to a cell of the tissue, wherein the cell expresses phosphatidylserine on the outer leaflet of the plasma membrane.

### Claim 5 (depends on 1)

The method of claim 1, wherein upon exposure of the IGF-1 variant to an IGF-1 receptor, the IGF-1 variant specifically activates the IGF-1 receptor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the IGF-1 variant induces the phosphorylation of serine/threonine protein kinase B (AKT).

### Claim 7 (depends on 1)

The method of claim 1, wherein the bi-specific protein further comprises a peptide linker.

### Claim 8 (depends on 7)

The method of claim 7, wherein the peptide linker is a human serum albumin, an Fc fragment or a variant thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the Annexin A5 variant is a non-internalizing variant of human Annexin A5 and wherein the bi-specific protein has a prolonged half-life as compared to a bi-specific protein comprising the amino acid sequence of wild-type human Annexin A5.

### Claim 10

A method to promote tissue regeneration or tissue survival, the method comprising:
administering topically to the patient in need thereof a topical composition comprising (a) a therapeutically effective amount of the bi-specific protein having (i) an activator domain, wherein the activator domain comprises a variant of human insulin-like growth factor IGF-1 having at least 95% identity to wild type human IGF-1 and comprising one or more mutations, wherein the one or more mutations consist of a substitution at one or more positions corresponding to E3, Y24, Y31, Y60, and combinations thereof, and (ii) a targeting domain, wherein the targeting domain comprises a variant of human Annexin A5 having at least 95% identity to wild type human Annexin A5 and comprising one or more mutations, wherein the one or more mutations consist of a substitution at the position corresponding to C316 and optionally at one or more positions corresponding to R63, K70, K101, E138, D139, N160 and combinations thereof, and (b) a pharmaceutically acceptable carrier.

### Claim 11

A topical composition comprising (a) a therapeutically effective amount of the bi-specific protein having (i) an activator domain, wherein the activator domain comprises a variant of human insulin-like growth factor IGF-1 having at least 95% identity to wild type human IGF-1 and comprising one or more mutations, wherein the one or more mutations consist of a substitution at one or more positions corresponding to E3, Y24, Y31, Y60, and combinations thereof, and (ii) a targeting domain, wherein the targeting domain comprises a variant of human Annexin A5 having at least 95% identity to wild type human Annexin A5 and comprising one or more mutations, wherein the one or more mutations consist of a substitution at the position corresponding to C316 and optionally at one or more positions corresponding to R63, K70, K101, E138, D139, N160 and combinations thereof, and (b) a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the bi-specific protein further comprises a peptide linker comprising a human serum albumin, an Fc fragment or a variant thereof.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the topical composition is a solution, a suspension, or an emulsion.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the topical composition is a suspension and wherein the topical composition further comprises an emulsifying agent.

### Claim 15

A topical composition comprising (a) a therapeutically effective amount of the bi-specific protein having (i) an activator domain, wherein the activator domain comprises a variant of human insulin-like growth factor IGF-1 comprising one or more mutations and having at least 95% identity to wild type human IGF-1, wherein the one or more mutations consists of an amino substitution at the position corresponding to position E3, an amino substitution at the position corresponding to position Y24, Y31 Y60, or combinations thereof, a deletion of amino acids 1-3, a deletion of amino acid R37, a deletion of amino acids 68-70, a 13-residue extension at the N-terminal or combinations thereof, and (ii) a targeting domain, wherein the targeting domain comprises a variant of human Annexin A5 having at least 95% identity to wild type human Annexin A5 and comprising one or more mutations, wherein the one or more mutations consist of a substitution at the position corresponding to C316 and optionally at one or more positions corresponding to R63, K70, K101, E138, D139, N160 and combinations thereof, and (b) a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the bi-specific protein further comprises a peptide linker comprising a human serum albumin, an Fc fragment or a variant thereof.

### Claim 17 (depends on 15)

The composition of claim 15, wherein the topical composition is a solution, a suspension, or an emulsion.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the topical composition is a suspension and wherein the topical composition further comprises an emulsifying agent.
